+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 121 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are studying patients with low-risk intermediate-stage nasopharyngeal carcinoma who have responded well to induction chemotherapy and have undetectable levels of plasma EBV-DNA. The trial compares two doses of radiotherapy targeting a specific low-risk area to evaluate their effects on survival, side effects, and quality of life. This phase 3 randomized study aims to find out if lower-dose radiotherapy can maintain treatment success while reducing toxicities related to treatment. Participants receive either reduced-dose radiotherapy 40.2Gy or conventional-dose radiotherapy 49.2Gy to the low-risk target volume called CTV2. Both groups undergo full-course immunotherapy with the PD-1 monoclonal antibody Tislelizumab, administered every three weeks, totaling 12 courses through induction, radiotherapy, and maintenance phases. Induction chemotherapy using a cisplatin-based regimen is given before radiotherapy. Treatment continues until toxicity, progression, withdrawal, or completion of planned courses. During the study, patients will be monitored for progression-free survival and serious adverse events over three years. Secondary measures include metastasis-free survival, relapse-free survival, overall survival, tumor response rates, and quality of life assessments using standard questionnaires over three years. Safety and effectiveness will be evaluated through imaging, laboratory tests, and clinical evaluations. The study enrollment includes adults aged 18 to 75 years, and the follow-up will provide information on long-term outcomes and treatment impact.

Age: 18Years - 75YearsAll GendersPhase 3
15 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of TQB2102 for injection compared to a standard drug regimen in the neoadjuvant treatment of HER2-positive early or locally advanced breast cancer. This phase III randomized, open-label, multi-center trial involves about 544 patients who will be assigned to receive either TQB2102 or a combination of Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin. The study aims to assess key outcomes such as total physiological complete response tpCR, breast pathological complete response bpCR, objective response rate ORR, event-free survival EFS, invasive disease-free survival IDFS, overall survival OS, and safety indicators including adverse events and immune response markers. Participants in the TQB2102 group will receive 8 cycles of intravenous infusion every 3 weeks, each cycle lasting 21 days. The comparator group will receive 6 cycles of a combination treatment with Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin, also administered intravenously every 3 weeks for 21-day cycles. After completing the assigned treatment cycles, all participants will undergo breast cancer surgery. Following surgery, there will be visits to monitor disease recurrence and overall survival. Throughout the study, participants will be closely monitored with evaluations conducted up to 50 months after study start. These include assessments of tumor response by independent review and investigators, safety monitoring from consent through 40 days post last dosing or surgery, and testing for anti-drug and neutralizing antibodies. Participants will have scheduled visits for treatment administration, surgery, and follow-up to track outcomes and safety over several years.

Age: 18Years - 75YearsAll GendersPhase 3
77 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of SPH5030 tablets in adults with Her2-positive or Her2-mutated biliary tract or colorectal cancer. This phase II clinical study focuses on patients with metastatic, unresectable, or advanced forms of these cancers who have specific genetic markers and meet certain health criteria. The study is sponsored by Shanghai Pharmaceuticals Holding Co., Ltd and aims to better understand treatment outcomes in this group. Participants will receive SPH5030 tablets orally once daily at a dose of 600 mg. The study is open-label and single-arm, meaning all participants receive the same treatment without a placebo group. The treatment period and follow-up span approximately two years, during which multiple outcome measures will be assessed. During the study, participants will undergo regular evaluations to monitor tumor response, duration of remission, disease control, progression-free survival, overall survival, and any adverse events related to treatment. Researchers will also assess safety through clinical and laboratory tests. The total involvement for each participant is about two years, allowing for detailed observation of treatment effects and tolerability.

Age: 18Years +All GendersPhase 2
30 locations
P

Actively Recruiting

Researchers are investigating the effects of an experimental drug called BNT323 also known as DB-1303 compared with standard chemotherapy in women with recurrent endometrial cancer that expresses the HER2 protein. This Phase III study includes two groups based on HER2 levels one group with lower HER2 expression 1 or 2 who have previously received immune checkpoint inhibitors, and another with higher HER2 expression 3. The study aims to evaluate how well these treatments control the cancer and their safety profiles. Participants in Cohort 1 will be randomly assigned to receive either BNT323 or a chemotherapy drug chosen by their doctor, such as doxorubicin or paclitaxel or docetaxel if paclitaxel is unsuitable. Cohort 2 participants will receive BNT323 alone. Treatments are given through intravenous infusions and continue until the cancer progresses, unacceptable side effects occur, or consent is withdrawn. The study includes screening, treatment lasting about six months, and long-term follow-up for up to 53 months to monitor survival and other outcomes. During the trial, participants will undergo various assessments including imaging scans to measure tumor size, evaluations of side effects, blood tests to study drug behavior and immune responses, and quality of life questionnaires. Safety follow-up occurs shortly after treatment ends, followed by extended monitoring for treatment effectiveness and survival. Participants are closely observed throughout to understand how well BNT323 works compared to chemotherapy and its impact on health and wellbeing.

Age: 18Years +FEMALEPhase 3
206 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a new drug called TQB2102 for Injection compared to a combination treatment of docetaxel, trastuzumab, and pertuzumab in adults with HER2 positive recurrent or metastatic breast cancer. This Phase III trial involves multiple centers and randomizes participants into two groups to compare these treatments. The study aims to better understand how well TQB2102 works and its safety profile in this patient population. Participants receive treatments through intravenous infusions every 21 days. One group is treated with TQB2102, a next-generation HER2 Antibody-Drug Conjugate, while the other group receives docetaxel combined with trastuzumab and pertuzumab following specific dosing schedules. Docetaxel is given once every three weeks for six cycles, trastuzumab starts with a loading dose followed by maintenance doses every three weeks, and pertuzumab is administered with an initial loading dose followed by maintenance doses every three weeks with observation after infusions. The study compares these two treatment approaches over the course of the trial. During the study, participants will undergo regular evaluations including imaging to assess tumor response, blood tests to monitor drug levels and immune responses, and tracking of any side effects or adverse events. The primary outcomes measured are the objective response rate and progression-free survival up to about 30 months. Secondary outcomes include overall survival, duration of remission, and detailed safety assessments up to around 52 months. The study also involves monitoring specific antibodies related to the drug and other laboratory markers to understand treatment effects fully.

Age: 18Years - 75YearsAll GendersPhase 3
25 locations
P

Actively Recruiting

Researchers are studying patients with advanced non-small cell lung cancer NSCLC who have a specific mutation in the EGFR gene and who do not clear circulating tumor DNA ctDNA after initial treatment with osimertinib alone. The goal is to explore the effectiveness and safety of combining osimertinib with sacituzumab tirumotecan in these patients. This is a phase II, multicenter, ctDNA-guided clinical trial that divides patients into groups based on their ctDNA status after initial osimertinib treatment. Participants first receive one cycle 3 to 5 weeks of osimertinib monotherapy at a standard oral dose of 80 mg daily. After this, tumor assessment and ctDNA testing determine their study group. Those with positive ctDNA results join Cohort 1, receiving osimertinib plus intravenous sacituzumab tirumotecan 4 mgkg every two weeks until disease progression, unacceptable side effects, or other criteria for stopping treatment. Those with negative ctDNA results continue osimertinib alone in Cohort 2, which is observational and allows physicians to manage treatment as usual. During the study, participants undergo regular tumor evaluations using imaging according to RECIST v1.1 criteria every six weeks in the first year and every 12 weeks thereafter, up to 36 months. Researchers monitor progression-free survival, response rates, overall survival, and adverse events. The study also collects safety data up to 30 days after treatment ends. Total participation can last up to three years depending on individual outcomes and treatment continuation.

Age: 18Years +All GendersPhase 2
4 locations
M

Actively Recruiting

Healthy Volunteer

Researchers are conducting a multi-center clinical study to assess artificial intelligence AI algorithms for measuring heart function and size using echocardiography. The study aims to compare AI measurements with those of physicians at different experience levels, evaluate the accuracy and stability of AI, and explore its use in complex heart conditions like cardiomyopathy, valve disease, and coronary heart disease. The goal is to improve diagnostic consistency and clinical workflows across medical centers. The study involves measuring cardiac chamber size and function in 1600 participants using AI, senior physicians, and intermediate physicians. All measurements are made with Mindray ultrasonic machines. AI and intermediate physician results are completed within one day after data collection, while senior physician results are completed within one month. The study will establish a standardized reference system for AI-assisted echocardiographic measurements and evaluate AIs performance in special cases. Participants will undergo echocardiographic scans with measurements of left and right ventricular size and function, Doppler ultrasound indicators, and valve annulus displacements. Researchers will analyze data to compare AI and physician measurements, assess measurement deviations, and evaluate AIs efficiency in reducing analysis time. The study will run until July 2026, with ongoing data collection and analysis across multiple centers, aiming to promote wider clinical application of AI technology for cardiovascular disease diagnosis.

Age: 18Years - 80YearsAll Genders
37 locations
E

Actively Recruiting

Researchers are evaluating the drug WS016 to treat hyperkalemia, a condition characterized by high potassium levels in the blood. This open-label Phase 3 clinical trial includes two phases a corrective phase aiming to reduce potassium levels within 24 to 72 hours, followed by a maintenance phase to keep potassium levels normal over a 12-month period in participants who meet specific criteria after the first phase. Participants first receive oral doses of WS016 12 grams three times daily during the corrective phase. Those whose potassium levels normalize enter the maintenance phase, receiving WS016 once daily at 12 grams, with dose adjustments based on potassium levels over the following 12 months. This study evaluates the long-term safety and effectiveness of WS016 in maintaining normal potassium levels. Throughout the study, participants undergo regular blood tests to monitor potassium levels and safety assessments during both phases. Researchers measure the percentage of participants maintaining potassium at or below 5.0 mmolL during the maintenance phase. Adverse events and changes in potassium are tracked closely. The total participation may last over a year, including both treatment phases and follow-up assessments.

Age: 18Years +All GendersPhase 3
50 locations
P

Actively Recruiting

Researchers are evaluating the preliminary safety and effectiveness of AL8326 tablets combined with Toripalimab in patients who have advanced recurrent or metastatic solid tumors. This open, non-randomized phase IIIa trial aims to find the recommended phase II dose and assess objective remission rates among these patients who have limited treatment options or have experienced progression after standard therapies. The study has two parts Phase 1 involves sequential cohorts receiving AL8326 plus Toripalimab 240 mg in 28-day cycles, with dose escalation based on tolerance. Phase 2a continues treatment with AL8326 administered orally daily at the recommended dose alongside Toripalimab 240 mg given in 21-day cycles. Treatment cycles continue for up to 24 months or until disease progression or unacceptable toxicity. Participants will undergo regular assessments including tumor response evaluations every 2 to 4 cycles depending on the phase, along with safety monitoring and laboratory tests. Outcomes measured include remission rates, duration of remission, disease control, progression-free survival, and overall survival. The study requires participants to comply with follow-up procedures and safety evaluations throughout the treatment and observation periods.

Age: 18Years +All GendersPhase 1Phase 2
15 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of hyperbaric oxygen therapy as a part of neoadjuvant treatment for women with breast cancer. This Phase II single-arm clinical study aims to explore how well hyperbaric oxygen works alongside standard chemotherapy before surgery, focusing on patients with specific types of invasive breast cancer. The study is sponsored by Guangdong Provincial Peoples Hospital and seeks to improve treatment outcomes for breast cancer patients. Participants will receive hyperbaric oxygen treatments at a pressure of 2.0 ATA with 100% oxygen for 60 to 90 minutes per session. Treatments are given at least five times during each chemotherapy cycle, totaling between 30 and 40 sessions over the course of the study. This intervention is combined with standard neoadjuvant chemotherapy cycles, each lasting three weeks, with up to eight cycles. During the study, participants will undergo assessments including tumor response evaluations using pathological complete response rates, imaging criteria, and tumor immune environment analysis. Quality of life will be measured at enrollment, before surgery, and three months after surgery. Side effects and treatment-related adverse events will be monitored throughout the therapy and for up to six months. The total participation duration spans approximately half a year, covering treatment and follow-up periods.

Age: 18Years - 60YearsFEMALEPhase 1Phase 2
2 locations

1-10 of 121

1